- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04770493
Enhancing the Effects of Alcohol Treatment With Lamotrigine
March 21, 2023 updated by: Brown University
Proof-of-Concept Clinical Trial of Lamotrigine as a Candidate Pharmacotherapy for Adolescent Alcohol Use Disorder
This study will help determine the tolerability and efficacy of the mood-stabilizing anticonvulsant lamotrigine in youth with alcohol use disorder.
It will also help establish whether and how lamotrigine improves outcomes related to alcohol use.
The results of this proof-of-concept study will inform whether a future larger clinical trial is warranted.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Adolescent alcohol use is a leading public health concern worldwide.
Clinical trials have tested a variety of psychosocial interventions with youth that yield only modest short-term benefits.
One potential way to improve treatments is to augment psychosocial interventions with pharmacotherapy.
The National Institutes of Health has mounted a concerted effort to identify medications that reduce drinking for nearly three decades.
Although this effort improved treatment for adults, no medication is indicated for adolescent use and randomized controlled trials with teenagers are almost nonexistent.
This gap raises key questions about whether and how medications could benefit youth.
Optimizing treatment options for youth requires closing this important gap.
Lamotrigine is safe with adolescents and does not adversely interact with alcohol.
Lamotrigine targets brain mechanisms implicated in alcohol use disorder, and it has shown to help treat adults with alcohol problems.
Yet, despite its widespread use with children and adolescents, no published double-blind, placebo-controlled studies have examined the effects of lamotrigine on drinking-related behavior in youth.
The purpose of this study is to determine how well teenagers accept lamotrigine plus alcohol education to reduce adolescent alcohol use.
This study will also tell us whether teenagers' alcohol use, craving, and enjoyment of drinking are reduced by lamotrigine.
Study Type
Interventional
Enrollment (Anticipated)
50
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Robert Miranda, PhD
- Phone Number: (401) 863-6658
- Email: Robert_Miranda_Jr@brown.edu
Study Contact Backup
- Name: Hayley Treloar Padovano, PhD
- Phone Number: (401) 863-6623
- Email: Hayley_Treloar@brown.edu
Study Locations
-
-
Rhode Island
-
Providence, Rhode Island, United States, 02903
- Recruiting
- Brown University Center for Alcohol and Addiction Studies
-
Contact:
- Robert Miranda, PhD
- Phone Number: 401-863-6658
- Email: Robert_Miranda_Jr@brown.edu
-
Contact:
- Brianna Parlette, MS
- Phone Number: 401 863-6687
- Email: Brianna_Parlette@brown.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 19 years (Child, Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- 16 to 19 years old, inclusive
- Self-reports consuming alcohol ≥ 2 days/week on average in the past 90 days of which ≥ 5 days involved ≥ 4 drinks within a 2-hr period (i.e., binge drinking) for boys and ≥ 3 drinks for girls
- Meet the DSM-5 criteria for alcohol use disorder (AUD)
- Be interested in reducing alcohol use
- Be able to read simple English
- Females taking estrogen-containing oral contraceptives have to agree to use secondary methods of birth control, such as condoms because lamotrigine lowers the effectiveness of estrogen-containing oral contraceptives. Sexually active females cannot be in this study if they do not agree to use a barrier method of birth control (condom) every time they engage in sexual intercourse.
Exclusion Criteria:
- Currently receiving formal AUD treatment
- Significant alcohol withdrawal symptoms
- Coexisting moderate or severe substance use disorder other than cannabis and nicotine, as defined by DSM-5 criteria.
- Positive urine toxicology screen any substances other than cannabis (THC)
- Currently taking a pharmacotherapy for AUD, a carbonic anhydrase inhibitor, or a glucuronidation
- Compelled to alcohol treatment by the justice system or has probation or parole requirements that might interfere with study participation
- History of rash that was serious, required hospitalization, or related to lamotrigine
- Have a history of any serious, unstable medical illness including seizures or hepatic, renal, gastroenterologic, respiratory, cardiovascular, endocrinologic, neurologic, immunologic, or hematologic disease
- Clinically significant abnormal liver function tests, including elevation of liver enzymes (AST, ALT) 3-fold above the upper limit of normal.
- Abnormal BUN and creatinine for renal impairment
- Renal or hepatic impairment
- Clinically significant abnormalities per physical exam, hematological assessment, bilirubin concentration, or urinalysis
- Pregnant, nursing, or refusing to use a condom, if female.
- Used psychotropic or anticonvulsant medication (prescribed by a health care professional) in the past 30 days (e.g., topiramate)
- Taking medications contraindicated with lamotrigine (e.g., valproate acid [Depakote], carbamazepine, phenytoin, phenobarbital, primidone, and rifampin, protease inhibitors lopinavir/ritonavir and atazanavir/lopinavi
- History of prior treatment with lamotrigine
- Known sensitivity or allergy to lamotrigine
- A previous history of drug reaction with eosinophilia and systemic symptoms (DRESS) or blood dyscrasias
- A history of Steven-Johnson syndrome or any presentation of symptoms suggestive of Steven-Johnson syndrome.
- Current or lifetime history of psychosis or suicidality
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Lamotrigine
Lamotrigine (25 mg/day to 200 mg/day in two divided doses) for 9 weeks
|
Participants will be randomized to lamotrigine (25 mg/day to 200 mg/day in two divided doses) for 9 weeks.
A comparator group will receive placebo (sugar pills).
Other Names:
|
Placebo Comparator: Placebo
Identical matching placebo capsules
|
Matching placebo (sugar pill)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Completion rates
Time Frame: 9-week active treatment phase
|
Percentage of youth who complete the active medication phase will determine feasibility.
|
9-week active treatment phase
|
Acceptability of the study medication
Time Frame: 9-week active treatment phase
|
Study withdrawal and the Client Satisfaction Questionnaire (CSQ-8), which ranges from 8-32 (higher scores indicate higher satisfaction) will determine acceptability
|
9-week active treatment phase
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Alcohol craving
Time Frame: 9-week active treatment phase
|
The primary measure of alcohol craving will be the following single-item: How strong is your craving to drink alcohol?
Scores range from 0 (none) to 20 (extremely strong).
|
9-week active treatment phase
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Robert Miranda, PhD, Brown University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 24, 2022
Primary Completion (Anticipated)
July 1, 2024
Study Completion (Anticipated)
October 1, 2024
Study Registration Dates
First Submitted
February 22, 2021
First Submitted That Met QC Criteria
February 22, 2021
First Posted (Actual)
February 25, 2021
Study Record Updates
Last Update Posted (Actual)
March 22, 2023
Last Update Submitted That Met QC Criteria
March 21, 2023
Last Verified
March 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Chemically-Induced Disorders
- Drinking Behavior
- Alcohol-Related Disorders
- Substance-Related Disorders
- Alcohol Drinking
- Alcoholism
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Antipsychotic Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Membrane Transport Modulators
- Anticonvulsants
- Sodium Channel Blockers
- Calcium-Regulating Hormones and Agents
- Calcium Channel Blockers
- Lamotrigine
Other Study ID Numbers
- 2004002676
- R21AA028394 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Per sponsor requirements, all data will be uploaded to the NIAAA Data Repository.
IPD Sharing Time Frame
One year after the completion of the project.
IPD Sharing Access Criteria
As required by the Sponsor, the data from this clinical trial will be uploaded to the National Institute on Alcohol Abuse and Alcoholism (NIAAA) data repository.
Like all NIAAA grants, the NIAAA will govern the access criteria.
IPD Sharing Supporting Information Type
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alcohol Use Disorder
-
Washington State UniversityRecruitingNicotine Use Disorder | Alcohol Use Disorder (AUD)United States
-
University of North Carolina, Chapel HillCompletedAlcohol Use Disorder, Mild | Alcohol Use Disorder, ModerateUnited States
-
Université du Québec à Trois-RivièresCompletedAlcohol Use, Unspecified | Alcohol Use Disorder, MildCanada
-
Woebot HealthStanford UniversityCompletedSubstance Use Disorders | Alcohol Use Disorder (AUD)United States
-
Medical University of South CarolinaNational Institute on Alcohol Abuse and Alcoholism (NIAAA); National Institutes...RecruitingAlcohol Drinking | Substance Use | Alcohol Use Disorder | Drinking, Alcohol | Alcohol Use Disorder (AUD)United States
-
Kaiser PermanenteNORC at the University of Chicago; Agency for Healthcare Research and Quality... and other collaboratorsCompleted
-
Centre Hospitalier Universitaire de NīmesRecruiting
-
Central Institute of Mental Health, MannheimNot yet recruitingAlcohol Use Disorder (AUD)Germany
-
Massachusetts General HospitalMbarara University of Science and TechnologyCompletedAlcohol Use Disorder (AUD)Uganda
-
ITAB - Institute for Advanced Biomedical TechnologiesNot yet recruitingNeurobiological Effects of Transcranial Direct Current Stimulation Treatment in Alcohol Use DisorderAlcohol Dependence | Alcohol-Related Disorders | Substance Use Disorders | Drug Abuse | Mental Disorder | Alcohol Abuse | Alcohol Use Disorder (AUD)
Clinical Trials on Lamotrigine
-
University of CincinnatiAmerican Epilepsy Society; Epilepsy FoundationCompleted
-
University of Maryland, BaltimoreCompleted
-
GlaxoSmithKlineCompletedEpilepsy, PartialUnited States, Korea, Republic of, Ukraine, Chile, Costa Rica, Russian Federation, Puerto Rico, Argentina
-
University of ChicagoCompletedDermatillomania | Pathologic Skin Picking | Neurotic Excoriation | Psychogenic ExcoriationUnited States
-
University of Maryland, BaltimoreFood and Drug Administration (FDA)Completed
-
University of CincinnatiAmerican Epilepsy Society; Epilepsy FoundationCompleted
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompletedMental DisordersUnited States
-
GlaxoSmithKlineCompleted